GLP1R and obesity due to melanocortin 4 receptor deficiency: Ultimately, the challenge lies in ensuring that the rapid expansion of DTC prescribing for GLP-1 therapies strengthens, rather than undermines, the broader goals of safe, effective, and patient-centered obesity care.